Clinical Trials Logo

Postpartum Hemorrhage clinical trials

View clinical trials related to Postpartum Hemorrhage.

Filter by:

NCT ID: NCT02983591 Completed - Clinical trials for Prevention of Post Partum Hemorrhage After Labor Induction

Effect of Misoprostol in Reducing Post Partum Hemorrhage After Labor Induction by Oxytocin

Start date: November 2016
Phase: N/A
Study type: Interventional

The use of Oxytocin for labor induction may cause receptor exhaustion and thus making its use in the third stage of labor ineffective in reducing post partum blood loss as compared to other uterotonics.So, we studied the effect of other uterotonic which is misoprostol in reducing post partum hemorrhage.

NCT ID: NCT02981758 Completed - Clinical trials for Post-partum Hemorrhage (PPH)

Accurate Display of Postpartum Hemorrhage Using Triton (ADOPT)

ADOPT
Start date: July 2016
Phase:
Study type: Observational

A comparison of reported estimated blood loss with quantified blood loss in all patients whose medical records indicate Triton was used during their vaginal delivery.

NCT ID: NCT02954068 Completed - Clinical trials for Postpartum Hemorrhage

IV Versus IM Administration of Oxytocin for Postpartum Bleeding

Start date: December 1, 2016
Phase: Phase 4
Study type: Interventional

This double-blind, randomized controlled trial will evaluate the effect of the route of administration of 10 IU of oxytocin on the average blood loss postpartum. Participants will be randomized to receive 10 IU of oxytocin by IV infusion or 10 IU of oxytocin by injection IM

NCT ID: NCT02910310 Completed - Clinical trials for Postpartum Hemorrhage

Introduction of UBT for PPH Management in Three Countries

UBT
Start date: October 2016
Phase: N/A
Study type: Interventional

This study is a prospective, systematic evaluation to assess the effectiveness and safety of introduction of UBT into PPH care at secondary level and district hospitals in 3 low-resource countries. The first component of the evaluation is a prospective stepped wedge cluster randomized design to assess the potential reduction in PPH-related mortality and invasive procedures (blood transfusion, arterial ligation, hysterectomy and uterine arterial embolization) for PPH performed at participating facilities following introduction of UBT. The second component is a nested cohort analysis to assess the safety and acceptability of UBT among women diagnosed with PPH.

NCT ID: NCT02884804 Completed - Clinical trials for Postpartum Hemorrhage

Study of Biological Determinants of Bleeding Postpartum

HPP-IPF
Start date: November 2011
Phase: N/A
Study type: Observational

At the entry of the delivery room, a standard blood analysis will be performed (Blood count, PT, aPTT, Fibrinogen, and D-Dimer) for each women (if they are agree), according to the center's practices. The percentage of the immature platelets is a an additional parameter on the hemogram. The clinical assessments (recorded in medical records) and biological values will be used to determine if there is a correlation between these data and the occurrence of postpartum hemorrhage.

NCT ID: NCT02883673 Completed - Clinical trials for Postpartum Hemorrhage

Safety and Effectiveness of the Jada System in Treating Primary Postpartum Hemorrhage

PEARLE
Start date: September 17, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of the Jada System in the control and reduction of primary postpartum hemorrhage.

NCT ID: NCT02861482 Completed - Clinical trials for Postpartum Hemorrhage

Early Usage of Bakri Ballon in Managing Postpartum Hemorrhage

Start date: January 2015
Phase: N/A
Study type: Interventional

Postpartum hemorrhage (PPH) is the top reason for maternal deaths in China. The four major causes of PPH include uterine atony, genital tract laceration, placenta factors and systemic medical disorders (including inherited and acquired coagulopathy). Management of PPH contains the application of uterotonic agents, using hemostasis agents, transfusion of blood component products, conservative procedures (intrauterine packing or balloon tamponade, compression sutures, vascular ligation and uterine artery embolization using sponges), and even hysterectomy. The Bakri Balloon has attained its efficacy and popularity ever since it was invented by Doctor YN. Bakri. Although it is recommended by many countries as a routine procedure for PPH management, the Bakri Balloon is not yet a first choice in China due to lack in clinical data of preventive usage. The aim of this study is to prove the efficacy and safety of the Bakri Balloon in early management of PPH.

NCT ID: NCT02816203 Completed - Clinical trials for Primary Postpartum Hemorrhage

Vacuum Device for Hemostasis in Obstetrics and Gynecology

HEMOGYN2
Start date: August 2016
Phase: N/A
Study type: Interventional

Postpartum hemorrhage (PPH), is the leading cause of maternal mortality and is responsible for approximately 25% of maternal mortality deaths.It is defined as blood loss in excess of 500 ml following vaginal childbirth. Primary (immediate) PPH occurs within the first 24 hours after delivery. In clinical practice, if after giving birth, the placenta is not expelled naturally, an active management should be triggered. After obstetric maneuvers therapeutic, options begin with uterotonic treatments before considering invasive treatments such as embolization, vessel ligation and hysterectomy. However, the morbidity associated with these techniques and the desire to preserve fertility mean that new therapeutic solutions have been conceived, which has recently led to the development of an innovative intrauterine hemostasis medical device : a hemostatic intrauterine suction cup. Assuming that postpartum hemorrhages are mainly due to uterine atony, we propose in this biomedical research, the study of a new medical device. Our hypothesis is that the uterine walls will append to the walls of the suction cup after the latter is put under vacuum. The actuation of the suction cup will lead to the aspiration of all sides of the uterus. Considering that postpartum haemorrhage is an emergency situation where vital prognosis of the patient is engaged, we selected to collect the consent of the patient using an emergengy procedure.

NCT ID: NCT02815605 Completed - Blood Transfusion Clinical Trials

Risk Factors, Management and Complications of Severe Post-partum Hemorrhage

PPH-REG
Start date: June 1, 2016
Phase:
Study type: Observational

The incidence of severe post-partum hemorrhage has been increasing in developed countries. The reason for this is at least partially unknown. Surgical techniques, holistic treatment protocols and strategies in blood product administration may have changed patient outcome and, for example the incidence of transfusion related side effects. A retrospective analysis of the whole cohort of parturients in 2009-2015 in Tampere University Hospital will be made to assess the risk factors for severe PPH (ie. estimated blood loss more than 1500ml during delivery) and examine the possible change in blood transfusion strategies and its effect on bleeding (for example, implementation of massive transfusion protocol, amount of blood products used, effect of red blood cell:fresh-frozen plasma ratio, use of pharmacological agents for coagulation management, introduction of new angiological and surgical techniques etc.) and complications, laboratory parameters and patient outcome.

NCT ID: NCT02806024 Completed - Cesarean Section Clinical Trials

Perioperative Administration of Tranexamic Acid for Placenta Previa and Accreta Study

TAPPAS
Start date: November 2016
Phase: Phase 4
Study type: Interventional

The purpose of this pilot study is to determine if intravenous tranexamic acid (TXA) is effective for reducing blood loss during high risk surgical procedures related to placenta previa and placenta accreta. TXA is currently used in other types of surgery for patients who are expected to have a large blood loss, such as orthopedic or open heart surgery.